Business Wire

SHARJAH-GOVERNMENT

6.6.2022 17:43:08 CEST | Business Wire | Press release

Share
Sir Bu Nair Island, a Safe Haven for Rare Creatures

Around midnight on June 1, a hawksbill turtle landed on the Sir Bu Nair Island. It’s one of the many that began arriving three months ago to nest on the island, bringing the number of nests to more than 300 spread across 27 beaches. The hawksbill turtle lays between 90 to 110 eggs and quietly returns to the sea, leaving eggs to hatch in 50 to 70 days. Part of Sharjah, Sir Bu Nair is situated around 110 km north off the Emirate’s coast.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005699/en/

Declared a nature reserve by a government decree, the island is one of the most important breeding grounds for the endangered hawksbill turtle and features on the International Union for Conservation of Nature list.

The enchanting island, 13 sq km in size, is home to the sooty seagulls (Abu Sannin) and other terns who make thousands of nests in its red soil. Sharjah has strict laws in place to protect all living creatures on the island. Sir Bu Nair is rich in rare green sea turtles, deer, hedgehogs and reptiles. It has also recorded the discovery of the red coat fish.

Rich history

Sir Bu Nair Island has long been preserved in the region’s collective memory of historical events. The British established, during their presence in the region, the first railway in the Emirates, whose relics remain on one side of the beach under the sea.

The island is also known for the sweetness of its waters, which is also fabled to cure rare diseases.

Pottery vessels have been found on the island dating back to the Iron Age, i.e. about 3,500 years ago confirming the continuation of marine activity on the island during the past 35 centuries. There is a cemetery on the island that is known to contain the remains of a number of divers and miners, which represents an important stage in the history of the development of the people living on the banks of the Arabian Gulf.

Mars Island

The island is also known as Al-Jazirah Al-Hamra because of its red terrain and is often compared to the planet Mars. It’s rich in minerals, including sulfur and iron oxide. In the past, railways were used to transport minerals to ships for exporting abroad. Some mines survive to this day.

Known for its sandy beaches and its pristine waters, Sir Bu Nair and its surroundings are rich in coral and marine life, boasting more than 76 types of fish and 40 types of coral reefs.

Emirati poets have long described Sir Bu Nair as “the tear that fell in the waters of the Gulf.” The people of Sharjah have a strong affinity with the island thanks to their historical love of the sea and seafaring traditions. The island had been the seat of generations of pearldivers and fishermen.

International importance

The Sir Bu Nair reserve enjoys strategic global importance and is included in the International Convention on Wetlands because of its rich marine life. It’s included in the preliminary list of UNESCO World Heritage Sites, and an international agreement on the protection and management of sea turtles in the Indian Ocean and Southeast Asia.

HH Sheikh Sultan bin Ahmed Al Qasimi, Deputy Ruler of Sharjah, attended the 22nd Sir Bu Nair Festival, held on June 3-4 to highlight the island's environmental and touristic importance and consolidate the Emirati relationship with their environment and heritage.

Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye